Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous and haemodialysis use. It is employed to prevent and treat venous thrombo‑embolism in at‑risk patients. GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen is a low molecular weight heparin used in the prevention and treatment of venous thrombo‑embolic disorders. - Prevention of deep vein thrombosis (DVT) in surgical patients: reduces the incidence of postoperative clot formation. - Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents propagation. - Prevention and treatment of pulmonary embolism: provides anticoagulation to lower the risk of embolic events. - Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clot formation.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection‑site bruising or pain: mild local irritation at the administration site. - Minor bleeding: such as epistaxis, gum bleeding or easy bruising. - Nausea or gastrointestinal discomfort: occasional transient upset. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Major bleeding: internal hemorrhage including gastrointestinal or intracranial bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline with paradoxical thrombosis. - Spinal or epidural hematoma: risk when combined with neuraxial anesthesia. - Severe allergic reaction: anaphylaxis, urticaria or angioedema. - Paradoxical thrombosis: clot formation despite therapy.

Careful assessment and monitoring are required when using enoxaparin. - Renal function: adjust dose or avoid use in severe renal impairment. - Platelet count: monitor regularly for thrombocytopenia, especially after 5‑10 days. - Concomitant anticoagulants: avoid or use with caution to reduce bleeding risk. - Active bleeding: contraindicated in patients with ongoing hemorrhage. - Surgical procedures: discontinue appropriately before neuraxial or invasive surgery. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increase bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect. - Thrombolytic therapy (e.g., alteplase): synergistic hemorrhagic potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding. - Neuraxial anesthesia or spinal puncture: risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., vancomycin, quinolones): may alter anticoagulant activity. - ACE inhibitors or ARBs: potential for enhanced anticoagulant effect. - Diuretics: may affect plasma volume and drug concentration. - Hormonal contraceptives or hormone replacement therapy: modest increase in thrombotic risk. - Lipid‑lowering agents (e.g., statins): occasional impact on platelet function.